GPT and hypophosphatemia: At the 1.5 mg/m2 dose in Schedule 1, 2 patients had DLTs (grade 4 hypophosphatemia [n = 1], grade 4 increased alanine aminotransferase/aspartate aminotransferase levels [ALT/AST; n = 1]).